to the cancer center. Pembrolizumab ED has been evaluated through pharmacokinetic studies and simulated model-based analyses, however clinical data are lacking. The aim of this study is to evaluate real-world outcomes and safety of ED vs standard
Search Results
CLO22-068: An Assessment of Extended Pembrolizumab Dosing and Outcomes in Advanced Non-Small Cell Lung Cancer Patients During the COVID-19 Pandemic
Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman, Andrea S. Fung, and Pierre-Olivier Gaudreau
HSR22-180: Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy in BRAF+ Cutaneous Melanoma Patients Treated in the Adjuvant Setting
Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah
use in the real-world setting is scarce. Objective : To examine treatment patterns and outcomes among BRAF+ cutaneous melanoma patients treated with adjuvant IO or DT in the United States. Methods: This was a retrospective cohort study using
HSR21-050: Access to Gastroenterology and Internal Medicine Physicians is Associated With Improved Outcomes in Colorectal Cancer: A Nation-Wide Analysis
Udhayvir Singh Grewal, Subhash Chandra Garikipati, Parth Rajeshbhai Shah, Shiva Jashwanth Gaddam, Aakash Rajendra Sheth, and Ghanshyam Mudigonda
conducted the current analysis to study the impact of access to various specialties on the overall outcomes in CRC patients. Materials and Methods: The National Provider Identifier (NPI) database was interrogated to identify the number of gastroenterology
Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction
Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa
Infusional 5-FU monotherapy has been used in patients with severe liver dysfunction, but the clinical outcomes have been disappointing. 8 FOLFOX and FOLFIRI have resulted in superior responses and survival rates compared with 5-FU alone. 9 However, the
Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits
Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh
within 2 years of biochemical recurrence. Additionally, consistent with other studies examining biochemical outcome after salvage RT, the survival benefit in this study cohort was seen only among men whose PSA became undetectable after salvage RT. 9
Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer
Bin-Yi Xiao, Xuan Zhang, Tai-Yuan Cao, Dan-Dan Li, Wu Jiang, Ling-Heng Kong, Jing-Hua Tang, Kai Han, Chen-Zhi Zhang, Wei-Jian Mei, Jian Xiao, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding
unresectable, and 3 refused surgery for unspecified reasons. Outcomes of Patients With Locally Advanced (cT4a/4b) Disease A total of 48 patients had locally advanced disease, with CR and PR observed in 4 (8.3%) and 37 (77.1%) of them, respectively; the
HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases
Naleen Raj Bhandari, Neha Bansal, Chi-Wei Duann, Anasofia Afonso, and Shen Zheng
and associated outcomes (time to treatment discontinuation [TTD] and treatment adherence) in selpercatinib-treated US patients. Methods: This retrospective cohort study used de-identified data from two administrative real-world claims databases
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg
worse outcome than tumors with other KIT or PDGFRA mutant isoforms or with no detectable mutation. 31 – 34 Conversely, KIT exon 11 mutations have been found in mitotically inactive GISTs 1 cm or less in size, suggesting that oncogenic KIT activity
Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer
Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess
study, which reported that the most common toxicities were myelosuppression and gastrointestinal adverse effects. 15 Table 4 Clinical Outcomes by Tumor Type Taking into consideration that patients had a median of 4 prior therapies, and
Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period
Aida Bujosa, Consolación Moltó, Thomas J. Hwang, José Carlos Tapia, Kerstin N. Vokinger, Arnoud J. Templeton, Ignasi Gich, Agustí Barnadas, Eitan Amir, and Ariadna Tibau
Background The FDA defines clinical benefit as an improvement in either the duration or the quality of life (QoL). 1 FDA criteria allow cancer drugs to be approved based on surrogate measures that will reasonably predict definitive outcomes
